Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.

Antiviral research - 1 Aug 2011

Goethals Olivia, Van Ginderen Marcia, Vos Ann, Cummings Maxwell D, Van Der Borght Koen, Van Wesenbeeck Liesbeth, Feyaerts Maxim, Verheyen Ann, Smits Veerle, Van Loock Marnix, Hertogs Kurt, Schols Dominique, Clayton Reginald F

Abstract excerpt

Raltegravir is the first integrase strand-transfer inhibitor (INSTI) approved for use in highly active antiretroviral therapy (HAART) for the management of HIV infection. Resistance to antiretrovirals can compromise the efficacy of HAART regimens. Therefore it is important to understand the emergence of resistance to RAL and cross-resistance to other INSTIs including potential second-generation INSTIs such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to HIV Integrase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Integrases

Share to Molecular Structure

Share to Plasma

Share to Pyrrolidinones

Share to Quinolones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 21669228
DOI: 10.1016/j.antiviral.2011.05.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.PMID 21669228Read ↗

Resistance to HIV integrase inhibitorsSemantic proximity Read ↗

Evolution of HIV integrase resistance mutations.Semantic proximity Read ↗

Patterns of resistance development with integrase inhibitors in HIVSemantic proximity Read ↗

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.Semantic proximity Read ↗

High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.Semantic proximity Read ↗

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Semantic proximity Read ↗

Resistance to Integrase InhibitorsSemantic proximity Read ↗

Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical IsolatesSemantic proximity Read ↗

Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.Semantic proximity Read ↗

Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.Semantic proximity Read ↗

Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.Semantic proximity Read ↗

Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.